Skip to main content
Insights

Explore our articles, audio-visual presentations, and scientific insights

Our scientific teams are committed to thought leadership and we regularly develop insights, webinars, and conference presentations to support knowledge-sharing within the industry. Contact us with any questions or to request slide decks.

blog insights

Watch HealthEconomics.com’s interview with David W. Miller on the unique challenges faced by biotech companies

Turning real-world data into decisions that change patient lives: A conversation with Allie Sosinsky and Katherine Donegan

In a recent publication, David W. Miller shares why the traditional drug development model is no longer sustainable

Access the slides and recording of our ISPOR 2025 presentation ‘Is IRA becoming America’s HTA?’. Online now.

Read David W. Miller’s article: ‘2025 Outlook: Key Trends Reshaping Life Sciences & Healthcare’

Download in-depth analysis of RPR-powered payer research into how the IRA’s maximum fair prices are reshaping the market.

Audio-visual presentations

Meeting the resource challenge: Why biotechs need a different kind of partner

HealthEconomics.com speaks with David W. Miller about the distinctive obstacles biotech firms encounter in developing evidence, securing market access, and engaging key stakeholders.

ISPOR 2025 presentation: Is IRA becoming America's HTA?

IRA Medicare drug price negotiation program introduces a negotiation mechanism for US drug pricing with HTA-like features. Is IRA a de-facto HTA body?

Discover how Genesis Research Group 'Innovates differently'

CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage with research partners.

Explore how evidence based pricing can inform global strategic launch decisions

Adam Weston explores how a data-driven, evidence-based pricing approach can inform strategic launch decisions and align clinical evidence with payer expectations, using Aduhelm and Leqembi as both cautionary tales and success stories.

Shining the light on vaccine market access

In March 2024, Genesis Research Group’s Katrin Nather and Tijana Ignjatovic presented at World EPA Congress on the subject of ‘Shining the light on vaccine market access’. Discover our RPR-powered access and pricing capabilities.

An introduction to the Flexible Integrated Team (FIT) engagement model

Our unique Flexible Integrated Team (FIT) engagement model represents a paradigm shift in how companies engage with a pharmaceutical, biotech and medical device research partners. Find out more.

Fit-for-purpose matchmaking

Earlier in 2024, our webinar ‘Fit-for-purpose matchmaking: a data selection and RWE approach for both regulatory and HTA audiences’ took place with Allie Sosinsky, Director, Pharmacoepidemiology and Safety, and Carole Longson MBE, Professor and Independent Senior Advisor. Explore our RWE expertise.

External control arms for regulatory and HTA agencies

In May 2023, Jen Wogen and Craig S. Parzynski presented at ISPOR 23 on ‘Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies.’ Discover our ECA and RWE capabilities.

Accelerating the generation of payer insights and evidence

Priti Jhingran and Tijana Ignjatovic present a HealthEconomics.com webinar describing how actionable payer insights facilitate an informed approach to evidence generation that is meaningful to payer, HTA, and medical decision-makers. Read more about RPR.

An introduction to our stakeholder engagement platform

RPR provides robust, transparent, survey-based stakeholder engagement in a fraction of the time and cost of traditional methods, plus the ability to ask participants clarificatory and follow-up questions. Read about RPR.

ITN Business interviews CEO David W. Miller

ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare industry talking about how best to confront its challenges.

Stakeholder validation of evidence generation plans

At the World EPA Congress in March 2023, VP, Evidence Strategy Priti Jhingran delivered a presentation on ‘Stakeholder Validation of Evidence Generation Plans (EGPs) to Achieve Optimal Access’. Read more about stakeholder insights.

Request slide decks or ask our RWE, HEOR, or market access experts a question

Get in touch

Read our CEO’s contribution to the October issue of Life Science Leader

Efficiency Is The New Normal by David W. Miller, Ph.D, CEO,
Genesis Research Group

View article online

Read our external control arm contribution to the July/August issue of ISPOR’s Value & Outcomes Spotlight

The Role of External Control Arms in Drug Development and Considerations for Success by Alexandra Z. Sosinsky, Craig S. Parzynski, and Deborah Casso

View article online

Read HealthEconomics.com’s exclusive interview with our CEO, David W. Miller on ‘Innovating Differently’

View article online

Articles

Sign up to receive regular thought leadership articles and videos, plus the latest RWE, HEOR, and market access trends

Sign up for our Newsletter

Headquarters:

HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US